Related Experiment Video
Updated: May 17, 2026
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
Published on: June 17, 2025
Mucous membrane pemphigoid: recent advances
Divya Srikumaran1, Esen K Akpek
1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Purpose Of Review:
This review article summarizes the recent literature in regards to advancements in the diagnosis and management of mucous membrane pemphigoid (MMP) published in the English literature since May 2011.
Recent Findings:
MMP is an uncommon, subepithelial blistering conjunctivitis that is commonly associated with vision loss. Distinct subgroups of MMP have recently been identified using advanced immunohistochemical techniques. Antiepiligrin MMP has been described as a distinct entity with a relationship to certain solid organ malignancies. There is evidence that conventional immunomodulators such as mycophenolate mofetil and biologics such as rituximab are effective in halting disease progression. Unfortunately, the majority of patients at presentation to tertiary centers already have advanced disease. Novel regenerative techniques such as stem cell therapy as well as traditional surgical approaches such as keratoprosthesis might be required for the restoration of vision in patients with significant corneal scarring.
Summary:
Despite advances in available immunosuppressive treatment regimens, significant ocular morbidity persists possibly secondary to difficulty in diagnosis. Additionally, absence of clinically detectable inflammation in a significant proportion of patients causes delay in the treatment and leads to progressive scarring. Surgical management of the complications of MMP remains challenging, with high failure rates over long-term follow-up.
Insights
Mucous membrane pemphigoid (MMP) diagnosis and management have advanced, yet ocular morbidity persists. Early detection and novel therapies are crucial for preventing vision loss from this rare blistering disease.
Area of Science:
- Ophthalmology
- Dermatology
- Immunology
Background:
- Mucous membrane pemphigoid (MMP) is a rare autoimmune subepithelial blistering disease affecting the conjunctiva.
- Ocular MMP frequently leads to significant vision impairment and scarring.
Purpose of the Study:
- To review recent advancements in the diagnosis and management of ocular mucous membrane pemphigoid (MMP).
- To highlight challenges in current treatment strategies and identify areas for future research.
Main Methods:
- Comprehensive literature review of English-language publications since May 2011.
- Analysis of diagnostic techniques, immunopathology, and therapeutic interventions for MMP.
Main Results:
- Distinct MMP subgroups identified, including antiepiligrin MMP associated with malignancies.
- Immunomodulators (mycophenolate mofetil) and biologics (rituximab) show efficacy in disease control.
- Advanced disease at presentation necessitates regenerative techniques (stem cell therapy) and surgical interventions (keratoprosthesis) for vision restoration.
Conclusions:
- Despite treatment advances, persistent ocular morbidity underscores diagnostic challenges and delayed treatment initiation.
- The absence of overt inflammation in some patients complicates early diagnosis and treatment, leading to progressive scarring.
- Surgical management of MMP complications remains difficult with high long-term failure rates.
